Stockreport

Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF EAST HANOVER, N.J., Dec. 9, 2019 /PRNewswire/ -- Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only C [Read more]